Serial assessments of cognitive functioning in individuals with Parkinson's disease (PD) are commonly used for the detection of incident dementia and neurobehavioral changes associated with treatments using neuromodulation (e.g., deep brain stimulation) and pharmacological agents (e.g., cholinesterase inhibitors). This study provides test-retest stability, expected practice effects, and practice-corrected reliable change indices for several commonly used neuropsychological tests from 62 older adults with mostly mild PD who underwent repeat evaluations approximately 17 months apart. At the group level, results showed adequate test-retest reliability (Spearman's rho range = 0.24-0.86) and generally small practice effects (Cohen's d range = 0.00-0.50). Application of reliable change indices using 90% confidence intervals showed the expected number of individuals (generally 10% or fewer) with statistically meaningful improvements (range = 0-12%) or declines (range = 2-8%) in cognitive performance at retest. Limitations discussed include ceiling effects at test baseline, sample homogeneity, interpretative cautions, and generalizability of study results. These data may be useful to researchers and clinicians interested in determining the statistical significance of changes in cognitive test performance in persons with PD over a 1-to 2-year interval.
(and diagnosis) of dementia, serial neuropsychological assessment has clinical utility in detecting both relatively subtle cognitive changes from baseline and dementia onset.
Serial neuropsychological evaluation also has relevance in the evaluation of treatment outcomes (Tröster, 2000) . Various dopamine replacement therapies (DRT) and anticholinergic medications used to treat PD motor symptoms can also affect cognition positively or negatively (e.g., Bedard et al., 1999; Brusa et al., 2003; Cools, Stefanova, Barker, Robbins, & Owen, 2002; Growdon, Kieburtz, McDermott, Panisset, & Friedman, 1998; Koller, 1984; Kulisevsky et al., 2000) , and cholinesterase inhibitors used to treat dementia are finding increasing application in PD (Aarsland, Mosimann, & McKeith, 2004) . Similarly, new surgical therapies, such as neuromodulation via subthalamic deep brain stimulation, may be associated with mild to moderate cognitive changes in a minority of patients (Parsons, Rogers, Braaten, Woods, & Tröster, 2006) . Given the increasing breadth of the therapeutic armamentarium with potential neurobehavioral effects for PD, it is important for researchers and clinicians to accurately establish whether observed changes in neuropsychological tests are meaningful.
Unfortunately, the determination of whether a score change is significant is particularly challenging in persons with neurological diseases, such as PD, because the disease is heterogeneous in the cognitive domains affected and progression of deficits. Multiple factors contribute to test score changes observed over time, including but not limited to test reliability, measurement error, practice effects, regression of scores to the mean, possible treatment effects and normal disease fluctuations. Practice effects occur when individuals undergo repeated evaluations using the same or similar test instruments. Consequently, it is conceivable that observed improvement in scores may not be due to an improvement in the function being assessed, but rather occurs because the individual remembers, or has experience with the test. In the case of healthy persons, such practice effects can often be estimated from test manuals. However, whilst test manuals often provide test-retest data and expected practice effects for normative samples, the test-retest intervals are often much shorter than those between evaluations done for clinical purposes and it cannot be assumed that test-retest gains observed in a normative sample are comparable to those evidenced within clinical populations. Indeed, supplementary data on test-retest effects in some clinical populations have been published to remedy this shortcoming (McCaffrey, Duff, & Westervelt, 2000) .
Prior longitudinal studies of cognition in PD have not provided test-retest scores corrected for practice or other effects, and thus provide little guidance in evaluating the significance or meaningfulness of test score changes over time. Nonetheless, these studies hint that, in PD patients without dementia, average score changes on many tests might be minimal (e.g., Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 2003; Schmand et al., 2000) . , examining change on the Mini Mental State Examination over 4 and 8 years, found that the mean annual rate of change among persons with PD who were not developing dementia was less than 1 point (and comparable to that witnessed in normal controls), whereas change in persons developing dementia was almost 2.5 points. Among 10 tests administered to 69 PD patients twice, 2 years apart, only four revealed statistically significant changes: average letter and semantic verbal fluency scores declined, but repetition of six-syllable phrases and name fluency increased (Azuma et al., 2003) . The 6-month change scores for the PD waitlist control group presented by Schmand et al. (2000) , although helpful in evaluating surgical treatment outcome in PD, pertain to a small sample of 15-16 highly selected patients (more severely afflicted surgical candidates) and thus may not be applicable to PD patients in general. Even in this more severely afflicted sample, score changes on memory tests (which are among the tests most susceptible to practice effects), were trivial (for example, 0.3 words for the Auditory Verbal Learning Test total recall score, and 0.3 points for the Logical Memory test evaluating immediate recall of prose passages).
The presence or absence of practice effects in clinical groups has important interpretative implications. If, as prior studies suggest, there indeed is a diminution (relative to normative samples) of practice effects in PD, then even small gains in scores after treatment might represent significant improvements, which might otherwise be attributed to the effects of repeated test exposure. Conversely, if practice effects are present in PD, then the absence of the expected practice effect or a seemingly small score decline might actually represent a significant decrement in performance. Because little data are available to facilitate interpretation of test score changes in PD, the aim of the present study was to provide test-retest stability, expected practice effects, and practice-corrected reliable change indices for several commonly used neuropsychological tests in older adults with PD. Since the matter of whether a given person with PD has deteriorated or improved cognitively may be more relevant clinically than the issue of whether a group of patients with PD has shown cognitive change, evaluation methods of the significance of change need to address possible practice effects. There are numerous methods of evaluating significance of change, including standardized regression-based approaches (e.g., McSweeney, Naugle, ) and a variety of reliable change indices (e.g., Lewis, Maruff, Silbert, Evered, & Scott, 2006) . The traditional Reliable Change Index (RCI; Jacobson & Truax, 1991) provides one criterion by which the clinician may establish whether or not an observed change is a meaningful one. Specifically, an RCI (alpha set to 0.10 (two-tailed)) greater than +1.645 is likely to occur randomly in only five percent of cases (p < 0.05), and is thus considered a significant change, while reliable decline occurs when values fall below −1.645. Modified RCI calculations make use of an additional adjustment for practice effects, in which the predicted score at time 2 (T 2 ) is the patient's time 1 (T 1 ) score plus the mean practice effect for the normative sample (Chelune, Naugle, Lüders, Sedlack, & Awad, 1993) . The adjusted RCI has been found to perform comparably to more complex regression formulas (e.g., Heaton et al., 2001; Temkin, Heaton, Grant, & Dikmen, 1999) and an adjusted RCI may aide the PD clinician in assuring that an observed change in a person with PD does not capitalize upon chance and is not a reflection of measurement error or practice effects. In situations where an RCI exceeds (in either a positive or negative direction) a predetermined segment of the normal distribution, the observed change is judged to be a reliable improvement or deterioration on a given criterion.
Method

Participants
Study participants included 62 older adults with PD who had undergone repeat neuropsychological evaluation within a tertiary care center's neurodegenerative disease research program. The initial evaluation in this study was each participant's first neuropsychological evaluation. Demographic and disease characteristics are presented in Table 1 . The diagnosis of PD was made on the basis of the presence of at least two of three cardinal signs (bradykinesia, rigidity, and tremor) and levodopa responsiveness. Exclusion criteria included: (1) clinical features of progressive supranuclear palsy or multiple system atrophy; (2) the presence of clinically apparent cognitive deficits prior to motor signs; (3) current severe psychiatric illness (e.g., major affective disorder, psychosis); (4) concurrent medical illness capable of compromising cognition; (5) history of supraspinal central nervous system disease other than PD. All participants were taking levodopa and/or dopamine agonists at the time of evaluation. At initial evaluation, seven patients were taking antidepressants, three were taking anxiolytics (benzodiazepines), and one patient was taking an anticholinergic. At the second evaluation, three patients were taking an antidepressant, four were taking anxiolytics, one was taking an anticholinergic, and one was taking an atypical antipsychotic. Because participants were part of a longitudinal study of cognition in PD, none participated in experimental pharmacotherapeutic or surgical treatments between neuropsychological evaluations.
Neuropsychological evaluation
A neuropsychological battery was completed by all 62 participants on two occasions approximately 17 months apart. Raw scores of select tests were drawn from the comprehensive neuropsychological test battery that included: Mattis Dementia Rating Scale (DRS; Mattis, 1988) , Controlled Oral Word Association Test (COWAT; Benton, Hamsher, & Sivan, 1994) , Boston Naming Test (BNT; Kaplan, Goodglass, & Weintraub, 1983) , Wisconsin Card Sorting Test (WCST; Heaton, Chelune, Talley, Kay, & Curtiss, 1993) , the Digit Span subtests (forward and backward) from the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Wechsler, 1981) , the Logical Memory I and II subtests from the Wechsler Memory Scale-Revised (WMS-R; Wechsler, 1987) , the California Verbal Learning Test (CVLT; Delis, Kramer, Kaplan, & Ober, 1987) , and the Beck Depression Inventory (Beck & Steer, 1993) . Due to time constraints and/or patient fatigue or cooperation factors, not all tests were administered to all participants. The tests were administered and scored according to standardized methods described in the published manuals.
Statistical analyses
A series of Spearman's rho correlation coefficients were conducted to evaluate test-retest reliability. Wilcoxon Ranked Sums Tests were used to assess the statistical significance of changes in test performance over time. The choice of nonparametric tests was based on the finding that 69% of the variables of interest were non-normally distributed (Shapiro-Wilk W Test p < .05). Note that, findings did not differ when parametric statistical tests were used; accordingly, unbiased Cohen's d values were generated to estimate the effect sizes associated with the observed practice effects. Individual-level change scores, correcting for measurement error and practice effects, were then calculated for each participant using a previously developed RCI methodology (e.g., Chelune et al., 1993; Heaton et al., 2001 ). The RCI method used to correct for measurement error and practice effects was defined as ((X 2 − X 1 ) − (M 2 − M 1 ))/S.D., where X 1 was the observed pretest score, X 2 was the observed posttest score, S.D. was the standard deviation of the group test-retest difference, M 1 was the group mean pretest score, and M 2 was the group mean posttest score. Practice effect correction involves the addition of a constant that is based upon the group-level average change (Heaton et al., 2001) . Reliable change was calculated by setting alpha to 0.10 (two-tailed) with a reliable improvement occurring when values exceeded +1.645, and reliable decline occurring when values fell below −1.645.
Results
Descriptive statistics, effect sizes, practice effects, reliability coefficients, and 90% RCI confidence intervals for the entire cognitive test battery are displayed in Table 2 . The median reliability coefficient was 0.67, with an interquartile range of 0.48-0.75. The weakest test-retest reliability results were found for subtests of the DRS (range = 0.24-0.59), while the largest reliability coefficients were observed on the CVLT (range = 0.66-0.86). Statistically significant practice effects were not observed on any test and only a few measures showed significant declines over time (e.g., DRS Construction). Consistent with this finding, effect size values (i.e., Cohen's d) associated with practice effects were small (median = 0.15, interquartile range = −0.09 to 0.26). Table 3 displays the base rates of significant improvements, declines, and stability on all of the cognitive tests as determined by the RCI methodology. Specifically, the 90% RCI confidence intervals displayed in Table 2 were applied to each individual participant's difference score (T 2 − T 1 ). Individuals whose difference scores fell within the 90% confidence interval were classified as cognitively "stable" on that test variable, whereas scores outside the confidence interval were designated as having significantly "improved" or "declined" as appropriate. The median percentage of participants with stable test scores was 92.3 (interquartile range = 88.6-93.9), while the median percentage of significant declines and improvements was 3.7% (interquartile range = 3.2-6.5) and 3.6% (interquartile range = 1.7-6.5), respectively.
Discussion
Overall, results from this observational study indicate that, at a group level, cognitive test performance is relatively stable in PD patients over a 17 month interval. This is consistent with a prior report on early, initially untreated PD patients re-tested after about 14 months (Kieburtz et al., 1994) and with reports of longitudinal evaluations over 2 years (Azuma et al., 2003) and 6 months in more advanced patients (Schmand et al., 2000) . Test-retest stability coefficients were generally adequate and consistent with literature on these same tests in which nonclinical samples were used (e.g., Delis et al., 1987) . Commensurate with prior investigations in PD (e.g., Azuma et al., 2003; Schmand et al., 2000) , this study did not find evidence of substantial practice-related changes in performance at retest for the majority of the cognitive variables. In contrast to findings from nonclinical samples (e.g., Basso, Bornstein, & Lang, 1999) , such findings suggest that observed improvements in cognitive functioning reported in studies of PD patients are not likely to be due to practice or other retesting effects. However, group-based practice effect statistics are of limited utility when evaluating individuals. As shown in Table 2 , despite the absence of significant practice effects at the group level, there was considerable variability in test performance over time, suggesting that particular subsets of individuals do in fact demonstrate cognitive improvements and declines that are obfuscated by the group-level statistics. Since not all patients with PD will demonstrate the average expected variability in cognitive performance, the PD-specific RCIs generated from this sample may aid clinicians and researchers who wish to assess whether observed changes on neuropsychological measures in individuals reflect statistically meaningful alterations in performance or changes due simply to practice effects. Although several regression-based approaches (e.g., Temkin et al., 1999) and alternative methods of computing RCIs (e.g., Lewis et al., 2006) are available for assessing cognitive change, the RCI practice effects model used in this study demonstrates generally comparable classification accuracy to regression-based methods (e.g., Heaton et al., 2001) and was selected for this study because it is arguably easier to use in clinic.
The primary aim of this manuscript was to employ observational data from a PD cohort to illustrate reliable change difference scores for PD research and clinical praxes. As such, the present study provides test-retest reliability coefficients, practice effects estimates, and RCIs for eight neuropsychological tests that are frequently used in assessing individuals with PD patients. For example, if an individual with PD were to be given a semantic verbal fluency task (animal fluency) approximately 12 months apart, the individual's total score would have to decline by eight or improve by six in order for the observed change to be considered statistically meaningful relative to other patients with PD. The use of RCIs specific to PD are most useful to the clinician attempting to determine whether potential progression of cognitive symptoms is unusual relative to PD patients and consequently might raise suspicion of dementia or a coexisting condition, such as depression or cerebrovascular disease, impacting cognition. Similarly, the tables provided here are likely to be useful when the clinician is trying to determine whether treatment (such as a medication or surgical intervention) has lead to unusual cognitive improvements or adverse events in PD. Careful interpretation of these clinical normative change standards is warranted because a patient with PD may improve (or decline) relative to their PD peers, but be classified as stable when nonclinical normative standards for change are applied (and the converse pattern may also occur). Accordingly, clinicians may also wish to interpret the observed difference scores in the context of published normative standards for cognitive change derived from healthy adults (e.g., Basso et al., 1999) , particularly when determining a PD-related decline has occurred from normal levels of cognition. Some have also advocated the use of multivariate normative techniques for detection of cognitive change in PD (Huizenga et al., 2007) . Whether normative standards derived from clinical and healthy populations yield comparable classification accuracy in identifying central nervous system insults and recovery remains to be determined.
A possible limitation to the interpretive efficacy of this study is the impossibility of improvement at T 2 (retest) on tests performed at ceiling level at test T 1 (baseline). This, however, does not appear to be an issue with most of the measures included in the current study. Only the DRS, WCST Categories and the BNT had average baseline performance within a standard deviation of perfect scores. Hence, a vast majority of the tests in this study still had substantial room for practice effects, and none were actually performed at ceiling level. A further possible limitation of the current study is the generalizability of study results, which are constrained by the nature and extent of the sample and the neuropsychological test battery used. Specifically, the sample in this study demonstrated generally intact or mildly impaired cognitive performance at initial evaluation and whether results generalize to more impaired groups is unknown. While the battery of the current study contains many measures commonly found in neurocognitive evaluations (Rabin, Barr, & Burton, 2005) , several of the tests in this study were older versions of tests now more widely used in clinical practice (e.g., WMS-R and CVLT). The reason for this is that data collection began when earlier test versions were the most current. Given the similarity between these tests' current and prior versions, it is probably appropriate to extrapolate current results to more recent test versions, although such extrapolation should be made with caution.
It is important to note that despite the relative interpretive ease of RCIs, clinicians should make judicious use of change indices and exercise their judgment when making treatment decisions. While the results of this study suggest that persons with PD manifest quite stable cognitive performance over time, demonstrating little evidence of practice effects, there were some areas in which practice effects were difficult to assess given ceiling effects. Further, interindividual (e.g., fatigue and effort) and external (e.g., changes in the testing environment) factors may be present and might influence the interpretation of changes in cognitive test scores over time . Patients with PD and dementia may show more precipitous cognitive declines and separate test-retest data remain to be published for persons with dementia so as to enable evaluation of treatment effects and determination of typical and unusual declines.
